Effects of carvedilol on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes

Life Sciences

Volumn 80, Issue 7, 2007, Pages 665-671

  Deng, Chunyu ^a   Yu, Xiyong ^a   Kuang, Sujuan ^a   Zhang, Wenchang ^a   Zhou, Zhiling ^a   Zhang, Kai ^b   Qian, Weimin ^a   Shan, Zhixin ^a   Yang, Min ^a   Wu, Shulin ^a   Lin, Shuguang ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Inform Technologies LLC   (United States)

Author keywords

Atrial fibrillation; Carvedilol; Human atrium; Ion channels; Transient outward K+ current; Ultra rapid delayed rectifier K+ current

Indexed keywords

CARVEDILOL; VOLTAGE GATED POTASSIUM CHANNEL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HEART ATRIUM MUSCLE; HEART REPOLARIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOLATED HEART; PATCH CLAMP; POTASSIUM CURRENT; TIMED DRUG RELEASE; WHOLE CELL;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; CARBAZOLES; DELAYED RECTIFIER POTASSIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART ATRIA; HUMANS; MIDDLE AGED; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; PROPANOLAMINES; TIME FACTORS;

EID: 33846068552     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.10.012     Document Type: Article

References (20)

1. 2+ current in rabbit ventricular myocytes. European Journal of Pharmacology 376 (1999) 189-201
2. Cheng J.H., Kamiya K., and Kodama I. Carvedilol and vesnarinone: new antiarrhythmic approach in heart failure therapy. Acta Pharmacologica Sinica 22 (2001) 193-200
3. + currents in mammalian cardiac and glial cells. Journal of Pharmacology and Experimental Therapeutics 254 (1990) 560-569
4. Hamill O.P., Marty A., Neher E., Sakmann B., and Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Archiv 391 (1981) 85-100
5. Joglar J.A., Acusta A.P., Shusterman N.H., Ramaswamy K., Kowal R.C., Barbera S.J., Hamdan M.H., and Page R.L. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. American Heart Journal 142 (2001) 498-501
6. Kajiwara K., Yanagita T., Nakashima Y., Wada A., Izumi F., and Yanagihara N. Differential effects of short and prolonged exposure to carvedilol on voltage-dependent Na+ channels in cultured bovine adrenal medullary cells. Journal of Pharmacology and Experimental Therapeutics 302 (2002) 212-218
7. Karle C.A., Kreye V.A., Thomas D., Rockl K., Kathofer S., Zhang W., and Kiehn J. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovascular Research 49 (2001) 361-370
8. Kawai K., Qin F., Shite J., Mao W., Fukuoka S., and Liang C.S. Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. American Journal of Physiology. Heart and Circulatory Physiology 287 (2004) H1003-H1012
9. Kawakami K., Nagatomo T., Abe H., Kikuchi K., Takemasa H., Anson B.D., Delisle B.P., January C.T., and Nakashima Y. Comparison of HERG channel blocking effects of various beta-blockers-implication for clinical strategy. British Journal of Pharmacology 147 (2006) 642-652
10. + current in human ventricular myocytes. Circulation Research 78 (1996) 689-696
11. McPhillips J.J., Schwemer G.T., Scott D.I., Zinny M., and Patterson D. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs 36 Suppl 6 (1988) 82-91
12. Morgan T., Anderson A., Cripps J., and Adam W. Pharmacokinetics of carvedilol in older and younger patients. Journal of Human Hypertension 4 (1990) 709-715
13. Naccarelli G.V., and Lukas M.A. Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clinical Cardiology 28 (2005) 165-173
14. Nattel S., Yue L., and Wang Z. Cardiac ultrarapid delayed rectifiers: a novel potassium current family of functional similarity and molecular diversity. Cellular Physiology and Biochemistry 9 (1999) 217-226
15. Ohlstein E.H., Douglas S.A., Sung C.P., Yue T.L., Louden C., Arleth A., Poste G., Ruffolo Jr. R.R., and Feuerstein G.Z. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 6189-6193
16. Ramaswamy K. Beta blockers improve outcome in patients with heart failure and atrial fibrillation: U. S. carvedilol study. Cardiac Electrophysiology Review 7 (2003) 229-232
17. Singh B.N. Beta-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview. Journal of Cardiovascular Pharmacology and Therapeutics 10 Suppl 1 (2005) S3-S14
18. Tian M., Dong M.Q., Chiu S.W., Lau C.P., and Li G.R. Effects of the antifungal antibiotic clotrimazole on human cardiac repolarization potassium currents. British Journal of Pharmacology 147 (2006) 289-297
19. + current similar to Kv1.5 cloned channel currents. Circulation Research 73 (1993) 1061-1076
20. Yuan Z., Shioji K., Kihara Y., Takenaka H., Onozawa Y., and Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Heart and Circulatory Physiology 286 (2004) H83-H90